A Scalable AI Approach for Clinical Trial Cohort Optimization
  FDA has been promoting enrollment practices that could enhance the diversity
of clinical trial populations, through broadening eligibility criteria.
However, how to broaden eligibility remains a significant challenge. We propose
an AI approach to Cohort Optimization (AICO) through transformer-based natural
language processing of the eligibility criteria and evaluation of the criteria
using real-world data. The method can extract common eligibility criteria
variables from a large set of relevant trials and measure the generalizability
of trial designs to real-world patients. It overcomes the scalability limits of
existing manual methods and enables rapid simulation of eligibility criteria
design for a disease of interest. A case study on breast cancer trial design
demonstrates the utility of the method in improving trial generalizability.
